Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury
NCT03035838 · Arun Gupta · EARLY_PHASE1 · withdrawn · last registry update 2022-11-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Alternate study commenced using different drug” | – | Registry record, Arun Gupta |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-17Results posted on the registry: M.D. Anderson Cancer Center, Netupitant + Palonosetron (NCT03040726)
- 2023-08-23Phase 3 first posted: Sichuan Cancer Hospital and Research Institute, Aprepitant Injection (NCT06007586)
- 2023-07-11Results posted on the registry: Duke University, Rolapitant + Ondansetron (NCT02991456)
- 2023-06-26Results posted on the registry: Heron Therapeutics, HTX-011 + aprepitant (NCT03718039)
- 2023-06-15Phase 3 first posted: Vanda Pharmaceuticals, Tradipitant + Placebo (NCT05903924)
- 2023-05-08Results posted on the registry: Alliance for Clinical Trials in Oncology, Palonosetron Hydrochloride + Ondansetron Hydrochloride (NCT03578081)
- 2023-03-10Results posted on the registry: Bayer, Elinzanetant (BAY3427080) + Placebo (NCT03596762)
- 2023-02-03Phase 3 first posted: Guangxi Medical University, Aprepitant in combination with granisetron and dexamethasone + Granisetron and dexamethasone (NCT05711823)
- 2022-12-23Results posted on the registry: Stanford University, Serlopitant Tablet + Placebo Oral Tablet (NCT03836001)
- 2022-10-20Phase 3 first posted: Bayer, Elinzanetant (BAY3427080) + Placebo (NCT05587296)
- 2022-10-03Phase 3 first posted: Shantou University Medical College, Fosaprepitant + tropisetron (NCT05564286)
- 2022-08-30Results posted on the registry: Heron Therapeutics, Aprepitant injectable emulsion + Saline Placebo (NCT04470622)
- 2022-08-22Phase 3 first posted: Fujian Shengdi Pharmaceutical Co., Ltd., HR20013 for injection；dexamethasone + fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone (NCT05509634)
- 2022-07-18Results posted on the registry: Stanford University, Fosaprepitant 150 mg (NCT03197064)
- 2022-05-03Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Selinexor + Melphalan (NCT02780609)
- 2022-04-26Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Ondansetron + Dexamethasone (NCT05346731)
- 2022-02-17Phase 3 first posted: Shi Yanxia, Olanzapine Tablets + Placebo (NCT05244577)
- 2022-02-16Phase 3 first posted: Henan Cancer Hospital, Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen + Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen (NCT05242874)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision